V025-2229 Screening compound: N-({[4-(4-chlorophenyl)-1-(3,4-dimethoxyphenyl)-1H-imidazol-2-yl]carbamoyl}methyl)-N-[2-(morpholin-4-yl)ethyl]propanamide

V025-2229 Screening compound: N-({[4-(4-chlorophenyl)-1-(3,4-dimethoxyphenyl)-1H-imidazol-2-yl]carbamoyl}methyl)-N-[2-(morpholin-4-yl)ethyl]propanamide
V025-2229 Screening compound: N-({[4-(4-chlorophenyl)-1-(3,4-dimethoxyphenyl)-1H-imidazol-2-yl]carbamoyl}methyl)-N-[2-(morpholin-4-yl)ethyl]propanamide alternative view

Chemical Structure Depiction of ChemDiv screening compound V025-2229
N-({[4-(4-chlorophenyl)-1-(3,4-dimethoxyphenyl)-1H-imidazol-2-yl]carbamoyl}methyl)-N-[2-(morpholin-4-yl)ethyl]propanamide

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

V025-2229

Molecular Formula

C28H34ClN5O5 (C28 H34 ClN5 O5)

Compound Name

N-({[4-(4-chlorophenyl)-1-(3,4-dimethoxyphenyl)-1H-imidazol-2-yl]carbamoyl}methyl)-N-[2-(morpholin-4-yl)ethyl]propanamide

IUPAC name

N-({[4-(4-chlorophenyl)-1-(34-dimethoxyphenyl)-1H-imidazol-2-yl]carbamoyl}methyl)-N-[2-(morpholin-4-yl)ethyl]propanamide

SMILES

CCC(N(CCN1CCOCC1)CC(Nc1nc(-c(cc2)ccc2Cl)cn1-c(cc1)cc(OC)c1OC)=O)=O

InChI

InChI=1S/C28H34ClN5O5/c1-4-27(36)33(12-11-32-13-15-39-16-14-32)19-26(35)31-28-30-23(20-5-7-21(29)8-6-20)18-34(28)22-9-10-24(37-2)25(17-22)38-3/h5-10,17-18H,4,11-16,19H2,1-3H3,(H,30,31,35)

InChI Key

GSVQSEQCHYYTLO-UHFFFAOYSA-N

MDL Number (MFCD)

MFCD19825267

Chemical and Physical Properties

Saltdata

not_available

Molecular Weight

556.06

Hydrogen Bond Acceptors Count

9.00

Hydrogen Bond Donors Count

1.00

Rotatable Bond Count

13.00

Number of Nitrogen and Oxygen Atoms

10

Partition Coefficient, logP

3.644

Distribution Coefficient, logD

3.617

Water Solubility, LogSw

-4.11

Polar Surface Area

79.267

Acid Dissociation Constant (pKa)

13.17

Base Dissociation Constant (pKb)

6.19

Number of Chiral Centers

0.00

Percent sp3 carbon bonding

39.30

V025-2229 in Drug Discovery

Included in Screening Libraries

MCL1 Targeted Library (12200 compounds)

Serine Proteases Inhibitors Library (32732 compounds)

Anti-HIV1 Library (19540 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Digestive system
  • Respiratory tract
  • Male
  • Female
  • Hemic and lymphatic
  • Infections
  • Cancer
  • Musculoskeletal
  • Digestive system
  • Respiratory tract
  • Male
  • Female
  • Cardiovascular
  • Skin
  • Metabolic
  • Immune system
  • Antiviral
  • Infections
  • Immune system
Targets:
  • Proteases

References: we are preparing a list of scientific research reports with V025-2229 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound V025-2229?
Check Price and Availability of V025-2229, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of V025-2229 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for V025-2229
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for V025-2229
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of V025-2229 available by request